Pharming Shareholders approve items on EGM agenda
(Thomson Reuters ONE) -
Company to focus on transition to commercial phase
Leiden, The Netherlands, March 30, 2010. Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today the
increase of its authorized share capital to 400 million shares, adjusting the
nominal value of the shares to ?0.04 and the strengthening of its Board of
Management with the appointment of Dr Rienk Pijpstra as Chief Medical Officer
(CMO). These decisions were taken by the Shareholders at an Extraordinary
Meeting (EGM) held today.
Pharming's authorized share capital prior to today's EGM was 200 million shares
with 154.5 million shares outstanding. The majority of the remaining 45.5
million shares was reserved to be able to convert the outstanding convertible
debt facilities of in total ?18.4 million to equity, if and when necessary.
Accordingly, the Shareholders today approved a proposal to increase the
authorized number of shares from 200 million to 400 million. In addition,
Pharming received approval to adjust the nominal value of the shares from ?0.50
to ?0.04.
In anticipation of the commercialization of Rhucin and the continued clinical
development of recombinant human C1 inhibitor in the follow-on indications such
as Antibody Mediated Rejection of and Delayed Graft Function in kidney
transplant, Pharming intends to strengthen its Board of Management with
additional senior management (pharmaceutical) industry experience in clinical
and financial positions during the course of 2010. As a first step, the
Shareholders have approved the proposal of the Board of Supervisory Directors to
appoint Dr. Rienk Pijpstra asChief Medical Officer effectively April 1, 2010.
Dr. Pijpstra will be responsible for the clinical development of Pharming's
products as well as drug safety, medical information and regulatory affairs. As
a result, the composition of the Board of Management will be as follows:
* Dr. Sijmen de Vries, Chief Executive Officer
* Dr. Bruno Giannetti, Chief Operations Officer
* Dr. Rein Strijker, Chief Commercial Officer
* Dr. Rienk Pijpstra, Chief Medical Officer (as per April 1, 2010)
Dr. Sijmen de Vries, Chief Executive Officer of Pharming: "We would like to
welcome Rienk on Pharming's Board of Management. We are looking forward working
together on the commercialization of Rhucin and further development for other
indications. 2010 will be a transformational year for Pharming in which we will
make the switch from R&D oriented company to a company with its first product on
the market."
Mr Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors, said: "We
are very pleased that the Shareholders have agreed to the proposed changes in
regard to Pharming's share capital.Securing the company's future and long-term
value for shareholders is our first priority. Achieving financial stability is
vital in order for Pharming to reach its corporate goals. The decisions taken
today provide a solid basis for the conditions to raise capital and strengthen
Pharming's financial position, which the Board of Supervisory Directors
considers priority for the Company."
At the EGM, the majority of the Shareholders also voted in favour of the
proposedoption arrangement for the CMO of Pharming and the amendment of the
Articles of Association of the Company. The revised Articles of Association can
be found on Pharming's website.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. Pharming's lead product Rhucin® for acute attacks of
Hereditary Angioedema has passed clinical development stage and the Market
Authorization Application is under review with the European Medicines Agency.
Prodarsan® is in early stage clinical development for Cockayne Syndrome and
lactoferrin for use in food products. The advanced technologies of the Company
include innovative platforms for the production of protein therapeutics,
technology and processes for the purification and formulation of these products,
as well as technology in the field of DNA repair (via DNage). Additional
information is available on the Pharming website,http://www.pharming.com
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1399284]
Press Release (PDF): http://hugin.info/132866/R/1399284/354822.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Clinuvel Pharmaceuticals Ltd.: FDA allows US clinical trials of afamelanotide in EPP
Datum: 30.03.2010 - 09:44 Uhr
Sprache: Deutsch
News-ID 1012208
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Leiden
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming Shareholders approve items on EGM agenda
"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
